Brussels Cuts Red Tape for Health Startups Into 2027

EMA and EISMEA signed a Letter of Intent on July 15, 2026, launching a joint program to help SMEs navigate EU health regulations faster.

28 Jul 2026

The European Medicines Agency and the European Innovation Council and SMEs Executive Agency have signed a Letter of Intent to streamline regulatory support for health innovators across the bloc. Signed on July 15, 2026, the agreement commits both bodies to a joint work programme running from 2026 to 2027. Startups, small and medium-sized enterprises, and research organisations are the intended targets, many of them lacking the regulatory expertise larger pharmaceutical companies rely on. EMA Executive Director Emer Cooke and EISMEA Director Momchil Sabev signed the agreement, underscoring commitment at the leadership level of both agencies.

Regulatory complexity under the EU's Medical Device Regulation and In Vitro Diagnostic Regulation has long delayed market entry for smaller developers. Without dedicated legal or regulatory teams, navigating these frameworks often means costly missteps, and sometimes abandoned projects.

The two agencies aim to intervene earlier. Engaging developers before products reach formal review is meant to help smaller organisations understand requirements upfront rather than learning through rejection. Whether this shortens approval timelines in practice remains to be tested — the Letter of Intent sets direction rather than binding targets.

For investors, the signal matters as much as the mechanism. Clearer regulatory pathways tend to reduce the uncertainty that weighs on early-stage funding decisions, particularly in medtech and biopharma, where development cycles are long and capital-intensive. A more predictable process could make Europe a steadier bet relative to other regions competing for the same investment.

None of this is a new challenge. EU officials have flagged fragmented regulatory guidance as a competitive weakness for years, even as they've expanded innovation funding through programmes like Horizon Europe. Pairing that funding push with tighter coordination on the compliance side addresses an area innovators have flagged as the more persistent obstacle.

Implementation is where the uncertainty lies. The joint work programme is now formally under way, but its concrete deliverables, and how EISMEA's innovation-support role will mesh day to day with EMA's scientific and regulatory authority, have yet to be detailed publicly. That detail will determine whether Tuesday's signature marks a meaningful shift for Europe's health startups, or another administrative gesture.